Vectura Group plc (VEC) - Financial and Strategic Analysis Review

Document Sample
Vectura Group plc (VEC) - Financial and Strategic Analysis Review Powered By Docstoc
					            Vectura Group plc (VEC) - Financial and Strategic Analysis Review

       Reference Code: GDME7949FSA                                                                                      Publication Date: AUG 2010

       One Prospect West, Chippenham Phone                         +44 1249 667700                      Revenue            40 (million GBP)
       Wiltshire                     Fax                           +44 1249 667701                      Net Profit         -16.70 (million GBP)
       SN14 6FH                                Website             www.vectura.com                      Employees          238
                                               Exchange            VEC [London Stock Exchange           Industry
       United Kingdom                                                                                                      Medical Equipment
                                                                   (LON)]

      Company Overview
       Vectura Group plc (Vectura) is a pulmonary drug development company, which is engaged in the development of a wide range of
       inhaled pharmaceuticals used for the treatment of respiratory, neurological and other diseases. Its formulation and device
       technologies are provided to other pharmaceutical companies on a licensing basis. Its product portfolio consists of eight marketed
       products and a portfolio of drugs in the clinical and pre-clinical development stage. The company's research and development
       facilities (R&D) are situated in Nottingham and Cambridge and is focused on the cosntant development on the existing products
       and for the improvisation of new upcoming products.

      Key Executives                                                              SWOT Analysis
                    Name                                   Title                  Vectura Group plc, SWOT Analysis
      Christopher Blackwell                 Chief Executive Officer               Strengths                 Weaknesses

      Anne P Hyland                         Chief Financial Officer
                                                                                     Intellectual Property              Limited Operating Margin
      John P Cashman                        Chairman
      Andrew J M Richards                   Director                                 Proven Inhalation                  Low Return on Equity
                                                                                     Technologies
      John R Brown, PhD                     Director
      Source: Annual Report, Company Website, Primary and Secondary Research
      GlobalData
                                                                                  Opportunities                         Threats
      Share Data
       Vectura Group plc                                                             Market Growth in Emerging          Industry Consolidation
       Share Price (GBP) as on 25-Aug-2010                                 0.50      Economies                          Challenges

       EPS (GBP)                                                          -0.03
                                                                                     Expansion of Manufacturing         Stringent Government
       Market Cap (million GBP)                                             165      Facility                           Regulations
       Enterprise Value (million GBP)                                       101

       Shares Outstanding (million) 
				
DOCUMENT INFO
Description: Vectura Group plc (Vectura) is a pulmonary drug development company, which is engaged in the development of a wide range of inhaled pharmaceuticals used for the treatment of respiratory, neurological and other diseases. Its formulation and device technologies are provided to other pharmaceutical companies on a licensing basis. Its product portfolio consists of eight marketed products and a portfolio of drugs in the clinical and pre-clinical development stage. The company's research and development facilities (R&D) are situated in Nottingham and Cambridge and is focused on the cosntant development on the existing products and for the improvisation of new upcoming products. Vectura Group plc Key Recent Developments Aug 06, 2010 Vectura And GSK Sign Agreement To License Some Of Vectura’s Dry Powder Drug Formulation Patents Nov 27, 2009 Boehringer Ingelheim Concludes Collaboration With Vectura Nov 27, 2009 Boehringer Ingelheim, Vectura Terminate Collaboration Jun 29, 2009 Novartis Initiates Phase-III Clinical Study Of NVA237 May 19, 2009 Vectura Posts Total Revenues Of GBP31.2 Million For Fiscal 2009 This comprehensive SWOT profile of Vectura Group plc provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better. The profile contains critical company information including, - Business description – A detailed description of the company’s operations and business divisions. - Corporate strategy – Analyst’s summarization of the company’s business strategy. - SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats. - Company history – Progression of key
BUY THIS DOCUMENT NOW PRICE: $125 100% MONEY BACK GUARANTEED
PARTNER GlobalData
GlobalData is an industry analysis specialist, providing business information products and services. GlobalData’s highly qualified team of analysts, researchers, and solution consultants use proprietary data sources, tools and techniques to gather, analyze and represent the latest and the most reliable information essential for a business to sustain a competitive edge. GlobalData is a UK-based company with presence across North America, Europe and Asia Pacific and has a broad product offering that ranges from interactive databases, reports and custom solutions. It is a comprehensive source of insights and analysis with coverage across the oil & gas, power, alternative energy, nuclear power, petrochemicals, medical equipment and healthcare industries. GlobalData has a broad range of coverage over key market segments. It has a global scope, covering a wide range of countries constituting more than 90% of global revenues in each of the industries it covers. With a large dedicated research and analysis capability, GlobalData employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries. Sectors and Geographies Covered GlobalData has a broad range of coverage over key market segments. It has a global scope, covering a wide range of countries constituting more than 90% of global revenues in each of the industries it covers. Research Methodology With a large dedicated research and analysis capability, GlobalData employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries.